Related Experiment Video

Updated: Mar 22, 2026

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

3.6K

[Antiarrhythmic effect of oligonucleotides accompanied by activation of HSP70 protein in the heart of rats]

S V Kruglov, O L Terekhina, E A Smirnova

    Patologicheskaia Fiziologiia I Eksperimental'Naia Terapiia
    |April 28, 2016
    PubMed
    Abstract

    Insights

    Oligonucleotides (OGN) significantly reduced arrhythmias during myocardial ischemia and reperfusion in rats. This protective effect is linked to increased HSP70 levels in the heart.

    Area of Science:

    • Cardiology
    • Molecular Biology
    • Pharmacology

    Context:

    • Myocardial ischemia and reperfusion (I/R) injury is a major cause of heart damage.
    • The protective mechanisms of oligonucleotides (OGN) against I/R injury are not fully understood.
    • Heat shock protein 70 (HSP70) is implicated in cellular protection during stress.

    Purpose:

    • To investigate the effect of OGN on arrhythmias induced by myocardial I/R.
    • To determine the impact of OGN on HSP70 levels in the heart.
    • To elucidate the role of HSP70 in OGN-mediated cardioprotection.

    Summary:

    • Male Wistar rats were pre-treated with the OGN drug "Derinat" for 7 days.
    • Arrhythmias were induced by left coronary artery occlusion and reperfusion, with intensity assessed by ECG.
    • HSP70 levels in the left ventricle were measured using Western-blot analysis.
    • "Derinat" significantly reduced extrasystolia, ventricular tachycardia, and ventricular fibrillation during ischemia and reperfusion.
    • The drug increased cardiac HSP70 levels by 65% compared to controls.

    Impact:

    • OGN administration markedly reduced the severity and duration of arrhythmias during myocardial I/R.
    • "Derinat" treatment led to a significant increase in HSP70 expression in the heart.
    • These findings suggest that OGN-induced activation of HSP70 synthesis contributes to enhanced cardiac resistance against I/R damage.

    More Related Videos

    Electrocardiogram Recordings in Anesthetized Mice using Lead II04:16

    Electrocardiogram Recordings in Anesthetized Mice using Lead II

    Published on: June 20, 2020

    14.6K
    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

    Published on: July 7, 2016

    9.0K

    Related Concept Videos

    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    1.8K
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
    2.9K
    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

    Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
    Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
    4.0K
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
    2.2K
    Mechanism of Cardiac Arrhythmias01:28

    Mechanism of Cardiac Arrhythmias

    Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
    2.6K
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    1.4K